Received: from AMSPR02MB215.eurprd02.prod.outlook.com (2603:10a6:206:1::33) by
 DB4PR02MB221.eurprd02.prod.outlook.com with HTTPS via
 AM5PR04CA0020.EURPRD04.PROD.OUTLOOK.COM; Mon, 3 Jul 2017 06:52:40 +0000
Received: from HE1PR02CA0100.eurprd02.prod.outlook.com (2603:10a6:7:29::29) by
 AMSPR02MB215.eurprd02.prod.outlook.com (2a01:111:e400:8022::14) with
 Microsoft SMTP Server (version=TLS1_2,
 cipher=TLS_ECDHE_RSA_WITH_AES_128_CBC_SHA256_P256) id 15.1.1220.11; Mon, 3
 Jul 2017 06:52:38 +0000
Received: from AM5EUR02FT016.eop-EUR02.prod.protection.outlook.com
 (2a01:111:f400:7e1e::201) by HE1PR02CA0100.outlook.office365.com
 (2603:10a6:7:29::29) with Microsoft SMTP Server (version=TLS1_2,
 cipher=TLS_ECDHE_RSA_WITH_AES_128_CBC_SHA256_P256) id 15.1.1178.14 via
 Frontend Transport; Mon, 3 Jul 2017 06:52:38 +0000
Authentication-Results: spf=pass (sender IP is 193.222.59.144)
 smtp.mailfrom=viforpharma.com; beobachter.ch; dkim=none (message not signed)
 header.d=none;beobachter.ch; dmarc=bestguesspass action=none
 header.from=viforpharma.com;
Received-SPF: Pass (protection.outlook.com: domain of viforpharma.com
 designates 193.222.59.144 as permitted sender)
 receiver=protection.outlook.com; client-ip=193.222.59.144;
 helo=mx1.viforpharma.com;
Received: from mx1.viforpharma.com (193.222.59.144) by
 AM5EUR02FT016.mail.protection.outlook.com (10.152.8.90) with Microsoft SMTP
 Server (version=TLS1_0, cipher=TLS_ECDHE_RSA_WITH_AES_256_CBC_SHA_P384) id
 15.1.1220.9 via Frontend Transport; Mon, 3 Jul 2017 06:52:37 +0000
Received: from mx1.viforpharma.com (localhost [127.0.0.1])
	by mx1.viforpharma.com (Mission Control Email Shield, 14141) with SMTP id 3x1HrN2x26z1J3ST
	for <sylke.gruhnwald@beobachter.ch>; Mon,  3 Jul 2017 08:52:36 +0200 (MEST)
Received: from trusted client by mx1.viforpharma.com; Mon Jul  3 08:52:36 2017
Authentication-Results-Original: vifor-mx002-ch-stg-1; dkim=none
Received: from trusted client by mx1.viforpharma.com; Mon Jul  3 08:52:36 2017
From: Vifor Pharma Media <media@viforpharma.com>
To: "sylke.gruhnwald@beobachter.ch" <sylke.gruhnwald@beobachter.ch>
CC: Vifor Pharma Media <media@viforpharma.com>
Subject: =?iso-8859-1?Q?RE:_Anfrage_Beobachter:_Offenlegung_der_Pharmazahlungen_ge?=
 =?iso-8859-1?Q?m=E4ss_PKK?=
Thread-Topic: =?iso-8859-1?Q?Anfrage_Beobachter:_Offenlegung_der_Pharmazahlungen_gem=E4?=
 =?iso-8859-1?Q?ss_PKK?=
Thread-Index: AdLzyHeyi+fQmWXvT6arXB8sm4S0YQ==
Date: Mon, 3 Jul 2017 06:52:35 +0000
Message-ID: <64ED3024CD0306498D62BE0C9531FD42A07FE841@SVPSGEXC01.viforpharma.galenica.group>
Accept-Language: en-GB, de-CH, en-US
Content-Language: en-US
X-MS-Has-Attach:
X-MS-TNEF-Correlator:
x-originating-ip: [172.22.129.193]
	boundary="_000_64ED3024CD0306498D62BE0C9531FD42A07FE841SVPSGEXC01vifor_"
MIME-Version: 1.0
Return-Path: media@viforpharma.com
X-MS-Exchange-Organization-Network-Message-Id: 10e7dcf1-ac20-4353-9ce4-08d4c1e01783
X-EOPAttributedMessage: 0
X-EOPTenantAttributedMessage: 1315698d-7807-4365-a9eb-4eb41341e0d4:0
X-MS-Exchange-Organization-MessageDirectionality: Incoming
X-Forefront-Antispam-Report: CIP:193.222.59.144;IPV:NLI;CTRY:CH;EFV:NLI;SFV:NSPM;SFS:(8046002)(2990300002)(438002)(189002)(252514010)(199003)(229853002)(53386004)(7066003)(106466001)(236005)(9686003)(6246003)(110136004)(54896002)(5660300001)(2351001)(224303003)(512934002)(2920100001)(224313004)(790700001)(16297215004)(15974865002)(57986006)(14003)(6306002)(6916009)(5640700003)(53546010)(3846002)(50986999)(54356999)(84326002)(6116002)(102836003)(55846006)(606006)(4326008)(1096003)(86362001)(189998001)(626005)(2501003)(356003)(33656002)(966005)(7736002)(7636002)(7596002)(15669805003);DIR:INB;SFP:;SCL:1;SRVR:AMSPR02MB215;H:mx1.viforpharma.com;FPR:;SPF:Pass;MLV:sfv;MX:1;A:1;LANG:de;
X-Microsoft-Exchange-Diagnostics: 1;AM5EUR02FT016;1: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
X-MS-Exchange-Organization-AuthSource: AM5EUR02FT016.eop-EUR02.prod.protection.outlook.com
X-MS-Exchange-Organization-AuthAs: Anonymous
X-MS-PublicTrafficType: Email
X-MS-Office365-Filtering-Correlation-Id: 10e7dcf1-ac20-4353-9ce4-08d4c1e01783
X-Microsoft-Antispam: UriScan:;BCL:0;PCL:0;RULEID:(300000500095)(300135000095)(300000501095)(300135300095)(22001)(300000502095)(300135100095)(23075)(8251501002)(300000503095)(300135400095)(71702078)(300000504095)(300135200095)(300000505095)(300135600095)(300000506095)(300135500095);SRVR:AMSPR02MB215;
X-Microsoft-Exchange-Diagnostics: 1;AMSPR02MB215;3: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
X-MS-TrafficTypeDiagnostic: AMSPR02MB215:
X-Microsoft-Exchange-Diagnostics: 1;AMSPR02MB215;25: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
 gawVxKW4jVskYz
X-Microsoft-Exchange-Diagnostics: 1;AMSPR02MB215;31: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;20:SkuZpqTwYT85F6EupoERQkSNwhdVnYWmZxEtFf4gqQTbPcGcWz3FbAk68q/YZV0zPypsBRujrKXFpy76B3aV/XoYjCkc56TfqnMXaBABNq9vwLRXdLmUoFov97mdbWNslntIW8/alxF/WCJs1/os9ODihBCQ3RtaJ/KbmtSaQ1c=
X-Exchange-Antispam-Report-Test: UriScan:(26388249023172)(148574349560750);
X-Exchange-Antispam-Report-CFA-Test: BCL:0;PCL:0;RULEID:(100000700101)(100105000095)(100000701101)(100105300095)(100000702101)(100105100095)(601004)(2401047)(8121501046)(13016025)(13018025)(9101536074)(93006095)(93004095)(3002001)(10201501046)(100000703101)(100105400095)(100000704101)(100105200095)(100000705101)(100105500095);SRVR:AMSPR02MB215;BCL:0;PCL:0;RULEID:(100000800101)(100110000095)(100000801101)(100110300095)(100000802101)(100110100095)(100000803101)(100110400095)(100000804101)(100110200095)(100000805101)(100110500095);SRVR:AMSPR02MB215;
X-Microsoft-Exchange-Diagnostics: 1;AMSPR02MB215;4: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
X-MS-Exchange-Organization-SCL: 1
X-Microsoft-Exchange-Diagnostics: =?us-ascii?Q?1;AMSPR02MB215;23:O4gz1W0keGvdnBQC8QVq/pDu9wz5tVOUFEkuU+g/dq?=
 =?us-ascii?Q?cNb5KwWMUFInrDMHlVUkL46UrUX8PzG1RasjCzuiVP1eu/Fs8SrK+bgWbXW2?=
 =?us-ascii?Q?mPWG1knneQEgln264lnP01DeU5sBo+3yDcIKr7TiyJrX95F8mS9btnTn41fT?=
 =?us-ascii?Q?sqdtQz3CXVddmd8vvATbj3LCkZG6uWnLb1tFELhxPFldxhiJfxCeNCikTI3e?=
 =?us-ascii?Q?q/MgJupaZSvMsr0hAPNvTTObliPvU+G2G7TDWyhqrfRWKVyoNYLLqqFq6T9D?=
 =?us-ascii?Q?J1d2qOc5O6G63fW80xDTC2wMZKjQLyvFC4TJPjiRvaw6Xs39bYOWPZe+9JPP?=
 =?us-ascii?Q?832rTpoUxkMa5T37KblQPjCnGwTAGisHV1bmKU/pkWVKBxBtl++uTzhslMc/?=
 =?us-ascii?Q?nHBbkZvneAKHpPuV+4JM4SylMtxMg/GHTvOEUqxFHWMSlmKfgcyjE+3P5vCj?=
 =?us-ascii?Q?enOy31cqAmJlSXqg/7DissT167Ml8mtq2vVyYLYuulKKL2PUL2+RVnLONSWc?=
 =?us-ascii?Q?Fafohh6iyWBa3vxoflrgx8aAUxE2X1XDQsnD3s/x9giKN1z/NbYx5QeD3gHq?=
 =?us-ascii?Q?4+z1ut+pEiwDcxyAIPLR6ZeIhTBERQOSIevkfl3S4OcuDU6QlPg42yyc6d6W?=
 =?us-ascii?Q?S5yPi0/3Eg1owbrkeS6iQ/kcl6TcgfUC5B0zNQGkJNRmDWROjtZxws3Xz2F8?=
 =?us-ascii?Q?1pUgy8rcqwbf6AT7Q4GFOtauO4+XLs6bhbRssNIYfiQV3ffVFA/pBdINWGkg?=
 =?us-ascii?Q?vrZBVFcN689lPn4nlhMAe/hpJM2qSVSAIZndLH0eaW/YETi1Q0RvvdooRHA3?=
 =?us-ascii?Q?o3Yinc5Tyjtm+OL8qhkA5hkWExiau4ZA+7cDc57TvB5AsDJbQiGjxpOQoSCx?=
 =?us-ascii?Q?iaAvA+u0msOgk/2DJI85PT97WSdlgqDc9T6fDmuYD6z2mPgnfRfzz7G8Brcq?=
 =?us-ascii?Q?0m/qdckXvS0iXsUrPbgeGZKg1yzm7XF378u/agtvDuZiFt5okNwP82sDMnpe?=
 =?us-ascii?Q?Ur8zwo4yei2OQNV2ijY6imshz9KuMeiKvxo80QoDEj1wSqQGpY2ae96PFzuh?=
 =?us-ascii?Q?olpLUQ3SX6LbbGCSUiCQn5h60/TTvD/p0gmZSjrIk6kkORS/oL7M3CL9B+95?=
 =?us-ascii?Q?jI4OUEv6P01HNNX/GXNw6LJcfs3Tb5YjMcx3b107KrcRQ97ztolN+deauJwj?=
 =?us-ascii?Q?k77C2fAqJSxHw=3D?=
X-Microsoft-Exchange-Diagnostics: 1;AMSPR02MB215;6: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
X-Microsoft-Exchange-Diagnostics: 1;AMSPR02MB215;5: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;24:DredOpjzSHEg6ch5h7MCaqsXyY4BHUbICJDkIfJXoP0bf0YKgT2th9smCLALR2PCscPmzW9tzNVv93PizdJrs1kyRPQ6Fq8CZ38bVMSvHiA=
SpamDiagnosticOutput: 1:99
SpamDiagnosticMetadata: NSPM
X-Microsoft-Exchange-Diagnostics: 1;AMSPR02MB215;7: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
X-MS-Exchange-CrossTenant-OriginalArrivalTime: 03 Jul 2017 06:52:37.0700
 (UTC)
X-MS-Exchange-CrossTenant-Id: 1315698d-7807-4365-a9eb-4eb41341e0d4
X-MS-Exchange-CrossTenant-FromEntityHeader: Internet
X-MS-Exchange-Transport-CrossTenantHeadersStamped: AMSPR02MB215
X-MS-Exchange-Transport-EndToEndLatency: 00:00:03.1478077
X-Microsoft-Exchange-Diagnostics:
	1;DB4PR02MB221;9:vqY4vAUrJg7pSGQxVcU0FoQSjwgnHEotiWxsS/y+Dxs3PFBg9kXmKGoeKiR3N/3peo6p5+QTg1GKkZN5wvxxQCdKMPJwcFuvOoP9KIkhkTWitjEAH4+Qd2OH5fuxlfHBvnKDjA50+Of59lFYWLw263EIuQl2UfeQrcMWAYbaxZVE3SXqxqvHipcNy83sNfyn48iAPEVKohsht/FPH/9yEx3i0r9g5D6rOaHmGcXd5PozQsLX/zU1QFsRL1szArNaumzDMTFFbc2hOs5eijPzowKxe9XLKM6tP6zPZfal90x1LpjO3NSsFOgW8f2dOd3eagbH/zTdFTBQ/5FYQFlRP7wlF6JJvNlbsGIGfiSnMVwQn0kURBiPTqMXqjetzFMGwt1ORp7PoQBXIMCmHOewjIy2FssSDF8dfdTNF4bhU6o=
X-Microsoft-Exchange-Diagnostics:
	1;DB4PR02MB221;27:nHA2itsFKMFSZR3+aY+9OheiH89jhmuHy7PDtGldZXO5ZKpJf62zG1j75iCLXjp8nyyURVvJukVqXOg99MqRIMM337dYoe0itKpu4uO7uziVdk7T5SxL4NSwWgNJjkmcizDDzi1mKtXn3mogS0Mj9w==
Content-type: multipart/alternative;
	boundary="B_3581922590_196038"

> This message is in MIME format. Since your mail reader does not understand
this format, some or all of this message may not be legible.

--B_3581922590_196038
Content-type: text/plain;
	charset="ISO-8859-1"
Content-transfer-encoding: quoted-printable

Sehr geehrte Frau Gruhnwald
=20
Gem=E4ss einschl=E4gigen Kodexvorgaben und analog zu letztem Jahr hat Vifor
Pharma alle 2016 stattgehabten geldwerten Leistungen am 30. Juni 2017 auf
ihrer Unternehmenswebsite  offengelegt:
http://www.viforpharma.com/de/ueber-vifor-pharma/transparenz.
Die Offenlegung erfolgt getrennt f=FCr Vifor Pharma und Vifor Fresenius
Medical Care Renal Pharma (VFMCRP).
=20
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) ist ein
Gemeinschaftsunternehmen der Vifor Pharma Gruppe (55% Anteil an VFMCRP) und
von Fresenius Medical Care  (45% Anteil an VFMCRP).
=20
Gem=E4ss dem EFPIA Disclosure Code (s. Link
<http://transparency.efpia.eu/uploads/Modules/Documents/efpia-disclosure-co=
d
e---august-2013-edited-final.pdf> ), dessen nationale Umsetzung f=FCr die
Schweiz als Pharmakooperationskodex (PKK) Niederschlag findet, sind die
EFPIA, resp. den nationalen Verb=E4nden (f=FCr die Schweiz: scienceindustries)
angeschlossenen Pharmaunternehmen gehalten, alle geldwerten Leistungen  von
Tochtergesellschaften und drgl. ebenfalls auszuweisen. Als
Mehrheitsanteilseignerin von VFMCRP ver=F6ffentlicht Vifor Pharma die
Leistungen von VFMCRP auf ihrer Website (siehe Link oben).
=20
Freundliche Gr=FCsse
Beatrix Benz
=20

Vifor Pharma Group=20
Vifor Pharma Management Ltd.
Beatrix Benz / Head of Global Communications & Public Affairs
Flughofstrasse 61 / CH-8152 Glattbrugg
Phone +41 58 851 80 00 / Fax +41 58 851 80 01
media@viforpharma.com / www.viforpharma.com <http://www.viforpharma.com>
=20

From: Gruhnwald Sylke [mailto:sylke.gruhnwald@beobachter.ch
<mailto:sylke.gruhnwald@beobachter.ch> ]
Sent: Donnerstag, 29. Juni 2017 13:53
To: Benz Beatrix
Subject: Anfrage Beobachter: Offenlegung der Pharmazahlungen gem=E4ss PKK
=20

Sehr geehrte Frau Benz,

=20

mein Name ist Sylke Gruhnwald, ich arbeite als Reporterin beim Beobachter =AD
aktuell an einer Recherche zu Zahlungen der Pharmaindustrie, offengelegt
gem=E4ss PKK.=20

=20

Wie ver=F6ffentlicht Vifor dieses Jahr die Zahlungen? Gemeinsam f=FCr Vifor
Pharma und Vifor Fresenius?

=20

Besten Dank im Voraus f=FCr Ihre R=FCckmeldung und freundliche Gr=FCsse, Sylke
Gruhnwald

=20

=20

Sylke Gruhnwald
Reporterin
=20
Beobachter

Ringier Axel Springer Schweiz AG

Flurstrasse 55

8021 Z=FCrich

=20

Tel: +41 (0)58 269 20 64

Mobil: +41 (0)76 737 79 14 =AD Threema und Signal verf=FCgbar

E-Mail: sylke.gruhnwald@beobachter.ch =AD PGP verf=FCgbar via keybase.io/sylke

=20

www.beobachter.ch <www.beobachter.ch>

=20



--B_3581922590_196038
Content-type: text/html;
	charset="ISO-8859-1"
Content-transfer-encoding: quoted-printable

<html>
<head>
<meta http-equiv=3D"Content-Type" content=3D"text/html; charset=3Dutf-8">
<meta name=3D"Generator" content=3D"Microsoft Word 14 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0cm;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
a:link, span.MsoHyperlink
	{mso-style-priority:99;
	color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{mso-style-priority:99;
	color:purple;
	text-decoration:underline;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-priority:99;
	mso-style-link:"Balloon Text Char";
	margin:0cm;
	margin-bottom:.0001pt;
	font-size:8.0pt;
	font-family:"Tahoma","sans-serif";}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-priority:99;
	mso-style-link:"Balloon Text";
	font-family:"Tahoma","sans-serif";}
span.EmailStyle19
	{mso-style-type:personal;
	font-family:"Arial","sans-serif";
	color:windowtext;}
span.EmailStyle20
	{mso-style-type:personal;
	font-family:"Arial","sans-serif";
	color:windowtext;}
span.EmailStyle21
	{mso-style-type:personal;
	font-family:"Arial","sans-serif";
	color:windowtext;}
span.EmailStyle22
	{mso-style-type:personal-reply;
	font-family:"Arial","sans-serif";
	color:windowtext;}
.MsoChpDefault
	{mso-style-type:export-only;
	font-size:10.0pt;}
@page WordSection1
	{size:612.0pt 792.0pt;
	margin:70.85pt 70.85pt 2.0cm 70.85pt;}
div.WordSection1
	{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext=3D"edit" spidmax=3D"1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext=3D"edit">
<o:idmap v:ext=3D"edit" data=3D"1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang=3D"EN-GB" link=3D"blue" vlink=3D"purple">
<div class=3D"WordSection1">
<p class=3D"MsoNormal"><span style=3D"font-size:10.0pt;font-family:&quot;Arial&=
quot;,&quot;sans-serif&quot;">Sehr geehrte Frau Gruhnwald<o:p></o:p></span><=
/p>
<p class=3D"MsoNormal"><span style=3D"font-size:10.0pt;font-family:&quot;Arial&=
quot;,&quot;sans-serif&quot;"><o:p>&nbsp;</o:p></span></p>
<p class=3D"MsoNormal"><span lang=3D"DE-CH" style=3D"font-size:10.0pt;font-family=
:&quot;Arial&quot;,&quot;sans-serif&quot;">Gem=E4ss einschl=E4gigen Kodexvorgabe=
n und analog zu letztem Jahr hat Vifor Pharma alle 2016 stattgehabten geldwe=
rten Leistungen am 30. Juni 2017 auf ihrer Unternehmenswebsite
 offengelegt: <a href=3D"http://www.viforpharma.com/de/ueber-vifor-pharma/tra=
nsparenz">
http://www.viforpharma.com/de/ueber-vifor-pharma/transparenz</a>.<o:p></o:p=
></span></p>
<p class=3D"MsoNormal"><span lang=3D"DE-CH" style=3D"font-size:10.0pt;font-family=
:&quot;Arial&quot;,&quot;sans-serif&quot;">Die Offenlegung erfolgt getrennt =
f=FCr Vifor Pharma und Vifor Fresenius Medical Care Renal Pharma (VFMCRP).<o:p=
></o:p></span></p>
<p class=3D"MsoNormal"><span lang=3D"DE-CH" style=3D"font-size:10.0pt;font-family=
:&quot;Arial&quot;,&quot;sans-serif&quot;"><o:p>&nbsp;</o:p></span></p>
<p class=3D"MsoNormal"><span lang=3D"DE-CH" style=3D"font-size:10.0pt;font-family=
:&quot;Arial&quot;,&quot;sans-serif&quot;">Vifor Fresenius Medical Care Rena=
l Pharma (VFMCRP) ist ein Gemeinschaftsunternehmen der Vifor Pharma Gruppe (=
55% Anteil an VFMCRP) und von Fresenius Medical Care
 (45% Anteil an VFMCRP). <o:p></o:p></span></p>
<p class=3D"MsoNormal"><span lang=3D"DE-CH" style=3D"font-size:10.0pt;font-family=
:&quot;Arial&quot;,&quot;sans-serif&quot;"><o:p>&nbsp;</o:p></span></p>
<p class=3D"MsoNormal"><span lang=3D"DE-CH" style=3D"font-size:10.0pt;font-family=
:&quot;Arial&quot;,&quot;sans-serif&quot;">Gem=E4ss dem EFPIA Disclosure Code =
(s.
<a href=3D"http://transparency.efpia.eu/uploads/Modules/Documents/efpia-discl=
osure-code---august-2013-edited-final.pdf">
Link</a>), dessen nationale Umsetzung f=FCr die Schweiz als Pharmakooperation=
skodex (PKK) Niederschlag findet, sind die EFPIA, resp. den nationalen Verb=E4=
nden (f=FCr die Schweiz: scienceindustries) angeschlossenen Pharmaunternehmen =
gehalten, alle geldwerten Leistungen
 von Tochtergesellschaften und drgl. ebenfalls auszuweisen. Als Mehrheitsan=
teilseignerin von VFMCRP ver=F6ffentlicht Vifor Pharma die Leistungen von VFMC=
RP auf ihrer Website (siehe Link oben).<o:p></o:p></span></p>
<p class=3D"MsoNormal"><span lang=3D"DE-CH" style=3D"font-size:10.0pt;font-family=
:&quot;Arial&quot;,&quot;sans-serif&quot;"><o:p>&nbsp;</o:p></span></p>
<p class=3D"MsoNormal"><span lang=3D"DE-CH" style=3D"font-size:10.0pt;font-family=
:&quot;Arial&quot;,&quot;sans-serif&quot;">Freundliche Gr=FCsse<o:p></o:p></sp=
an></p>
<p class=3D"MsoNormal"><span lang=3D"DE-CH" style=3D"font-size:10.0pt;font-family=
:&quot;Arial&quot;,&quot;sans-serif&quot;">Beatrix Benz</span><span lang=3D"DE=
-CH" style=3D"font-size:10.0pt;font-family:&quot;Arial&quot;,&quot;sans-serif&=
quot;"><o:p></o:p></span></p>
<p class=3D"MsoNormal"><span lang=3D"DE-CH" style=3D"font-size:10.0pt;font-family=
:&quot;Arial&quot;,&quot;sans-serif&quot;"><o:p>&nbsp;</o:p></span></p>
<div>
<p class=3D"MsoNormal"><b><span style=3D"font-size:10.0pt;font-family:&quot;Ari=
al Black&quot;,&quot;sans-serif&quot;">Vifor Pharma Group&nbsp;</span></b><o=
:p></o:p></p>
<p class=3D"MsoNormal"><span style=3D"font-size:10.0pt;font-family:&quot;Arial&=
quot;,&quot;sans-serif&quot;">Vifor Pharma Management Ltd.
</span><o:p></o:p></p>
<p class=3D"MsoNormal"><span style=3D"font-size:10.0pt;font-family:&quot;Arial&=
quot;,&quot;sans-serif&quot;">Beatrix Benz&nbsp;/ Head of Global Communicati=
ons &amp; Public Affairs
<br>
Flughofstrasse 61 / CH-8152 Glattbrugg <br>
Phone &#43;41 58 851 80 00 / Fax &#43;41 58 851 80 01</span><o:p></o:p></p>
</div>
<p class=3D"MsoNormal"><u><span style=3D"font-size:10.0pt;font-family:&quot;Ari=
al&quot;,&quot;sans-serif&quot;;color:blue"><a href=3D"mailto:media@viforpharm=
a.com">media@viforpharma.com</a></span></u><span style=3D"font-size:10.0pt;fon=
t-family:&quot;Arial&quot;,&quot;sans-serif&quot;">&nbsp;/
</span><span style=3D"font-size:10.0pt"><a href=3D"http://www.viforpharma.com">=
<span style=3D"font-family:&quot;Arial&quot;,&quot;sans-serif&quot;">www.vifor=
pharma.com</span></a><o:p></o:p></span></p>
<p class=3D"MsoNormal"><span style=3D"font-size:10.0pt"><o:p>&nbsp;</o:p></span=
></p>
<div>
<div style=3D"border:none;border-top:solid #B5C4DF 1.0pt;padding:3.0pt 0cm 0c=
m 0cm">
<p class=3D"MsoNormal"><b><span lang=3D"DE-CH" style=3D"font-size:10.0pt;font-fam=
ily:&quot;Tahoma&quot;,&quot;sans-serif&quot;">From:</span></b><span lang=3D"D=
E-CH" style=3D"font-size:10.0pt;font-family:&quot;Tahoma&quot;,&quot;sans-seri=
f&quot;"> Gruhnwald Sylke [</span><span lang=3D"EN-US" style=3D"font-size:10.0pt=
;font-family:&quot;Tahoma&quot;,&quot;sans-serif&quot;"><a href=3D"mailto:sylk=
e.gruhnwald@beobachter.ch"><span lang=3D"DE-CH">mailto:sylke.gruhnwald@beobach=
ter.ch</span></a></span><span lang=3D"DE-CH" style=3D"font-size:10.0pt;font-fami=
ly:&quot;Tahoma&quot;,&quot;sans-serif&quot;">]
<br>
<b>Sent:</b> Donnerstag, 29. </span><span lang=3D"EN-US" style=3D"font-size:10.=
0pt;font-family:&quot;Tahoma&quot;,&quot;sans-serif&quot;">Juni 2017 13:53<b=
r>
<b>To:</b> Benz Beatrix<br>
<b>Subject:</b> Anfrage Beobachter: Offenlegung der Pharmazahlungen gem=E4ss =
PKK<o:p></o:p></span></p>
</div>
</div>
<p class=3D"MsoNormal"><span lang=3D"EN-US"><o:p>&nbsp;</o:p></span></p>
<div>
<div>
<div>
<p class=3D"MsoNormal"><span lang=3D"EN-US" style=3D"font-size:10.5pt;font-family=
:Consolas;color:black">Sehr geehrte Frau Benz,<o:p></o:p></span></p>
</div>
<div>
<p class=3D"MsoNormal"><span lang=3D"EN-US" style=3D"font-size:10.5pt;font-family=
:Consolas;color:black"><o:p>&nbsp;</o:p></span></p>
</div>
<div>
<p class=3D"MsoNormal"><span lang=3D"EN-US" style=3D"font-size:10.5pt;font-family=
:Consolas;color:black">mein Name ist Sylke Gruhnwald, ich arbeite als Report=
erin beim Beobachter =AD aktuell an einer Recherche zu Zahlungen der Pharmaind=
ustrie, offengelegt gem=E4ss PKK.&nbsp;<o:p></o:p></span></p>
</div>
<div>
<p class=3D"MsoNormal"><span lang=3D"EN-US" style=3D"font-size:10.5pt;font-family=
:Consolas;color:black"><o:p>&nbsp;</o:p></span></p>
</div>
<div>
<p class=3D"MsoNormal"><span lang=3D"EN-US" style=3D"font-size:10.5pt;font-family=
:Consolas;color:black">Wie ver=F6ffentlicht Vifor dieses Jahr die Zahlungen? G=
emeinsam f=FCr Vifor Pharma und Vifor Fresenius?<o:p></o:p></span></p>
</div>
<div>
<p class=3D"MsoNormal"><span lang=3D"EN-US" style=3D"font-size:10.5pt;font-family=
:Consolas;color:black"><o:p>&nbsp;</o:p></span></p>
</div>
<div>
<p class=3D"MsoNormal"><span lang=3D"EN-US" style=3D"font-size:10.5pt;font-family=
:Consolas;color:black">Besten Dank im Voraus f=FCr Ihre R=FCckmeldung und freund=
liche Gr=FCsse, Sylke Gruhnwald<o:p></o:p></span></p>
</div>
<div>
<p class=3D"MsoNormal"><span lang=3D"EN-US" style=3D"font-size:10.5pt;font-family=
:Consolas;color:black"><o:p>&nbsp;</o:p></span></p>
</div>
<div>
<p class=3D"MsoNormal"><span lang=3D"EN-US" style=3D"font-size:10.5pt;font-family=
:Consolas;color:black"><o:p>&nbsp;</o:p></span></p>
</div>
<div>
<div>
<div>
<p class=3D"MsoNormal"><span lang=3D"EN-US" style=3D"font-family:&quot;Arial&quot=
;,&quot;sans-serif&quot;;color:black">Sylke Gruhnwald</span><span lang=3D"EN-U=
S" style=3D"color:black"><o:p></o:p></span></p>
<p class=3D"MsoNormal"><span lang=3D"EN-US" style=3D"font-family:&quot;Arial&quot=
;,&quot;sans-serif&quot;;color:black">Reporterin</span><span lang=3D"EN-US" st=
yle=3D"color:black"><o:p></o:p></span></p>
<p class=3D"MsoNormal"><span lang=3D"EN-US" style=3D"color:black"><o:p>&nbsp;</o:=
p></span></p>
<p class=3D"MsoNormal"><span lang=3D"EN-US" style=3D"font-family:&quot;Arial&quot=
;,&quot;sans-serif&quot;;color:black">Beobachter</span><span lang=3D"EN-US" st=
yle=3D"color:black"><o:p></o:p></span></p>
</div>
<div>
<p class=3D"MsoNormal"><span lang=3D"EN-US" style=3D"font-family:&quot;Arial&quot=
;,&quot;sans-serif&quot;;color:black">Ringier Axel Springer Schweiz AG</span=
><span lang=3D"EN-US" style=3D"color:black"><o:p></o:p></span></p>
</div>
<div>
<p class=3D"MsoNormal"><span lang=3D"EN-US" style=3D"font-family:&quot;Arial&quot=
;,&quot;sans-serif&quot;;color:black">Flurstrasse 55</span><span lang=3D"EN-US=
" style=3D"color:black"><o:p></o:p></span></p>
</div>
<div>
<p class=3D"MsoNormal"><span lang=3D"EN-US" style=3D"font-family:&quot;Arial&quot=
;,&quot;sans-serif&quot;;color:black">8021 Z=FCrich</span><span lang=3D"EN-US" s=
tyle=3D"color:black"><o:p></o:p></span></p>
</div>
<div>
<p class=3D"MsoNormal" style=3D"margin-bottom:12.0pt"><span lang=3D"EN-US" style=3D=
"color:black"><o:p>&nbsp;</o:p></span></p>
</div>
<div>
<p class=3D"MsoNormal"><span lang=3D"EN-US" style=3D"font-family:&quot;Arial&quot=
;,&quot;sans-serif&quot;;color:black">Tel:&nbsp;&#43;41 (0)58 269 20 64</spa=
n><span lang=3D"EN-US" style=3D"color:black"><o:p></o:p></span></p>
</div>
<div>
<p class=3D"MsoNormal"><span lang=3D"EN-US" style=3D"font-family:&quot;Arial&quot=
;,&quot;sans-serif&quot;;color:black">Mobil:&nbsp;&#43;41 (0)76 737 79 14&nb=
sp;=AD&nbsp;Threema und Signal verf=FCgbar</span><span lang=3D"EN-US" style=3D"color=
:black"><o:p></o:p></span></p>
</div>
<div>
<p class=3D"MsoNormal"><span lang=3D"EN-US" style=3D"font-family:&quot;Arial&quot=
;,&quot;sans-serif&quot;;color:black">E-Mail:&nbsp;<a href=3D"mailto:sylke.gru=
hnwald@beobachter.ch">sylke.gruhnwald@beobachter.ch</a>&nbsp;=AD&nbsp;PGP verf=
=FCgbar via&nbsp;<a href=3D"keybase.io/sylke">keybase.io/sylke</a></span><span l=
ang=3D"EN-US" style=3D"color:black"><o:p></o:p></span></p>
</div>
<div>
<p class=3D"MsoNormal"><span lang=3D"EN-US" style=3D"font-family:&quot;Arial&quot=
;,&quot;sans-serif&quot;;color:black">&nbsp;</span><span lang=3D"EN-US" style=3D=
"color:black"><o:p></o:p></span></p>
</div>
<div>
<p class=3D"MsoNormal"><span lang=3D"EN-US" style=3D"color:black"><a href=3D"www.be=
obachter.ch"><span style=3D"font-family:&quot;Arial&quot;,&quot;sans-serif&quo=
t;">www.beobachter.ch</span></a><o:p></o:p></span></p>
</div>
</div>
<div>
<p class=3D"MsoNormal"><span lang=3D"EN-US" style=3D"font-size:10.5pt;font-family=
:&quot;Calibri&quot;,&quot;sans-serif&quot;;color:black"><o:p>&nbsp;</o:p></=
span></p>
</div>
</div>
</div>
</div>
</div>
</body>
</html>


--B_3581922590_196038--

